LGND Earnings

Quarterly EPS
$-1.64
Q4 2024
$-2.21
Q1 2025
$0.25
Q2 2025
$5.99
Q3 2025
$2.33
Q4 2025
$-0.67
Q1 2026
$2.42
Q2 2026
$-1.43
Q3 2026
Latest Revenue78.7M
Latest Net Income-28485000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q3 2026-$1.4378.7M-28485000-31.8%-123.9%
Q2 2026$2.4263.7M48.5M+33.7%+868.0%
Q1 2026-$0.6751.7M-13345000+14.1%+69.7%
Q4 2025$2.3359.7M44.8M+39.4%+242.1%
Q3 2025$5.99115.5M117.3M+122.8%+1,635.9%
Q2 2025$0.2547.6M4.8M+14.7%+108.7%
Q1 2025-$2.2145.3M-42451000+46.3%-145.5%
Q4 2024-$1.6442.8M-31088000+52.4%-257.7%
Q3 2024-$0.3951.8M-7172000——
Q2 2024-$2.8841.5M-51911000——
Q1 2024$4.8631.0M86.1M——
Q4 2023$1.0428.1M18.2M——
Ligand Pharmaceuticals (LGND) — Earnings